Chemistry:Merigolix

From HandWiki

Merigolix (INN; developmental code names HS-10518, NCE-403, SKI-2670, TU-2670) is a gonadotropin releasing hormone (GnRH) antagonist which is under development for the treatment of endometriosis and uterine fibroids.[1][2][3][4][5] It is taken by mouth.[1] The drug is being developed by TiumBio, Daewon Pharmaceutical, and Jiangsu Hansoh Pharmaceutical.[1][2] As of October 2024, it is in phase 2 clinical trials for both endometriosis and uterine fibroids.[1][2]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 "Merigolix". 28 October 2024. https://adisinsight.springer.com/drugs/800065270. 
  2. ↑ 2.0 2.1 2.2 "Delving into the Latest Updates on Merigolix with Synapse". 22 February 2025. https://synapse.patsnap.com/drug/b6fc8cc4b81242688c2bee2d9d3f9726. 
  3. ↑ "Recent Development of Non-Peptide GnRH Antagonists". Molecules 22 (12): 2188. December 2017. doi:10.3390/molecules22122188. PMID 29232843. 
  4. ↑ "Uterine fibroids: an update on current and emerging medical treatment options". Therapeutics and Clinical Risk Management 15: 157–178. 2019. doi:10.2147/TCRM.S147318. PMID 30774352. 
  5. ↑ "Highlights on Medical Treatment of Uterine Fibroids". Current Pharmaceutical Design 27 (36): 3821–3832. 2021. doi:10.2174/1381612826666210101152820. PMID 33388011. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Merigolix&oldid=4035400"